Systemic inflamation and prognosis in lung cancer stage I-II

Introduction: The TNM classification is widely used to determine the prognosis in lung cancer (LC). However, it shows some variability in about 30% of patients. Systemic inflammation is present in LC and its role in prognosis is poorly understood. Hypothesis: Systemic inflammation and oxidative stress are inversely related to LC prognosis in patients with initial LC (Stage I-IIp). Aims: To evaluate the influence of serum cytokines and oxidative stress variables in LC relapse and mortality in a cohort of patients that underwent lug surgery for a stage I-II. Population and Methods: We studied a cohort of 207 patients (66±9 yrs, 85% Men, 97% smokers [50% former]) surgically treated for LC that are being followed during 5 years. We obtained blood samples from all of them to analyse in serum: cytokines (IL-6, IL-8, IL-10, IFNg, TNFa receptors 1,2) by ELISA, C Reactive Protein (CRP) and fibrinogen (nefelometry) carboniles and nitrotyrosines (ELISA). The actual follow up is 2 years. Results: The main histology was Adenocarcinoma and epidermoid carcinoma (46 and 44%, respectively). The CRP was increased (5.1±6 mg/L, p Conclusions: In patients with LC surgically treated and in stage I-IIp, systemic inflammation is associated with a higher relapse and mortality. The integration of these biomarkers to other variables (TNM) could improve the prognosis prediction. Funded by isciii PI12/01310